Trials / Recruiting
RecruitingNCT05672121
Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
A Phase I/II, Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 42 (estimated)
- Sponsor
- Chengdu Origen Biotechnology Co., Ltd. · Industry
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
KH631 is a adeno-associated virus (AAV) vector-based gene therapy for subretinal injection. The long-term, stable therapeutic protein after one time injection for nAMD could potentially reduce the treatment burden and maintain vision.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KH631 | KH631: AAV vector containing a coding sequence for an anti-VEGF protein |
Timeline
- Start date
- 2023-02-06
- Primary completion
- 2026-12-28
- Completion
- 2026-12-28
- First posted
- 2023-01-05
- Last updated
- 2024-11-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05672121. Inclusion in this directory is not an endorsement.